Drug/Dose | N | Duration | Follow-up | VRET | SVR | Study |
---|---|---|---|---|---|---|
IFN α2a 9MU/m 3×/wk | 14 | 48 wks | 6 months | 71% | 43% | Farci, 1994 [145] |
IFN α2a 3MU/m 3×/wk | 14 | 48 wks | 6 months | 36% | 14% | |
Placebo | 14 | 48 wks | 6Â months | 0% | 8% | |
IFN α2b 18MU 3×/wk. + | 16 | 6 months | 18 months | 31% | – | Madejon, 1994 [146] |
  9MU 3×/wk. + |  | 1 month |  |  |  | |
  6MU 3×/wk. + |  | 1 month |  |  |  | |
  3MU 3×/wk |  | 4 months |  |  |  | |
IFN α2a 3MU/day + | 16 | 3 months | 18 months | 25% | – | |
1.5MU | 9Â months | Â | Â | Â | ||
Ribavirin 15Â mg/kg/day | 9 | 4Â months | 12Â months | 11% | 11% | Garripoli, 1994 [147] |
Famciclovir | 15 | 6Â months | 6Â months | 6.60% | 13.30% | Yurdaydin, 2002 [148] |
Lamivudine 100Â mg/day + Placebo | 11 | 52Â +Â 52 wks | 16 wks | 9.0% | 0% | Niro, 2005 [121] |
Lamivudine 100Â mg/day | 20 | 104 wks | 16 wks | 10% | 10% | |
INF α 2a 9MU 3×/wk. | 10 | 24 months | 6 months | 50% | 20% | Günsar, 2005 [125] |
INF α 2a 9MU 3×/wk. + Ribavirin 1–1,2 g/day | 21 | 24 months | 6 months | 52% | 23% | |
Peg-INF α 2b 1.5 μg/kg/wk | 14 | 12 months | 16 months | 57% | 43% | Castelnau, 2006 [149] |
Peg-INF α 2b 1.5 μg/kg/wk | 12 | 12 months | 12 months | – | 17% | Erhardt, 2006 [122] |
Peg-IFN α 2b 1.5 μg/kg/wk. | 16 | 18 months | 6 months | 19% | 25% | Niro, 2006 [150] |
Peg-IFN α 2b 1.5 μg/kg/wk. + Ribavirin 800 mg/day + | 22 | 12 months | 6 months | 9% | 18% | |
Peg-IFN α 2b 1.5 μg/kg/wk. | 6 months | |||||
INF α 2b 10MU 3×/wk | 12 | 12 months | 24 months | 42% | 17% | Canbakan, 2006 [151] |
INF α 2b 10MU 3×/wk. + Lamivudine | 14 | 12 months | 24 months | 64% | 28% | |
IFN α 2a 9MU 3×/wk | 8 | 12 months | 6 months | 50% | 50% | Yurdaydin, 2008 [152] |
Lamivudine + | 14 | 2Â months | 6Â months | 50% | 36% | |
IFN α 2a 9MU 3×/wk. + Lamivudine | 10 months | |||||
Lamivudine | 17 | 12Â months | 6Â months | 12% | 12% | |
Peg-INF α 2b 1.5 μg/kg/wk | 49 | 13 months | 26 months | 33% | 25% | Gheorge, 2011 [128] |
Peg-INF α 2b 1.5 μg/kg/wk | 11 | 24 months | 6 months | 56% | – | Örmeci, 2011 [153] |
7 | 12 months | 6 months | 57% | – | ||
Peg-IFN α 2b 180 μg/wk. + Adefovir 10 mg/day | 31 | 12 months | 6 months | 23% | 26% | Wedemeyer, 2011 [154] |
Peg-IFN α 2b 180 μg/wk. | 29 | 12 months | 6 months | 24% | 31% | |
Adefovir 10Â mg | 30 | 12Â months | 6Â months | 0% | 0% | |
Entecavir 1 g/day | 13 | 48 wks | 6 months | 23% | – | Kabaçam, 2012 [124] |
Peg-IFN α 2a 180 μg/wk. ou 2b 1.5 μg/kg/wk | 32 | 24 months | 6 months | 50% | 47% | Karaca, 2013 [155] |
Peg-IFN α 2b 180 μg/wk. + Entecavir | 22a | 12 months | 6 months | 95% | 95% | Borzacov, 2016 [135] |